Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Pollack, C
  • Reilly, PA
  • Verhamme, P
  • Bernstein, R
  • Dubiel, R
  • Eikelboom, John
  • Huisman, M
  • Hylek, E
  • Kam, C-W
  • Kamphuisen, PW
  • Kreuzer, J
  • Levy, JH
  • Sellke, F
  • Steiner, T
  • Wang, B
  • Weitz, Jeffrey

publication date

  • June 1, 2015